During the three and six months ended June 30, 2021 and 2020, APC paid approximately $0.6 million and $0.4 million, respectively, and $1.0 million and $1.0 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).

During the three and six months ended June 30, 2021 and 2020, APC paid approximately $1.7 million and $0.9 million, respectively, and $3.2 million and $2.6 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).

During the three and six months ended June 30, 2021 and 2020, APC paid approximately $30,000 and $0.1 million, respectively, and $51,000 and $0.1 million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.

During the three and six months ended June 30, 2021 and 2020, APC paid approximately $19,000 and $25,000, respectively, and $52,000 and $76,000, respectively, to Fresenius Medical Care (“Fresenius”) and their subsidiaries for services as a provider. During the three and six months ended June 30, 2021 and 2020, APAACO paid approximately $0.2 million and $0.2 million, respectively, and $0.3 million and $0.3 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company’s board members is an officer of Fresenius.

During the three and six months ended June 30, 2021 and 2020, APC paid approximately $0.3 million and $0, respectively, and $0.4 million and $0, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shared a common board member with the Company.

During the three months ended June 30, 2021 and 2020, APC paid an aggregate of approximately $8.2 million and $9.0 million to shareholders, respectively, which included approximately $2.2 million and $3.0 million, respectively, to shareholders who are also officers of APC. During the six months ended June 30, 2021 and 2020, APC paid an aggregate of approximately $15.6 million and $16.3 million to shareholders, respectively, and $3.8 million and $4.8 million, respectively, to shareholders who are also officers of APC.

During the three and six months ended June 30, 2021 and 2020, the Company paid approximately $0 and $0.1 million, respectively, and $0 and $0.2 million, respectively, to Critical Quality Management Corporation (“CQMC”) for an office lease. CQMC shares common ownership with certain board members of APC.

For the three and six months ended June 30, 2021 and 2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.2 million and $0.2 million, respectively, to Numen, LLC (“Numen”) for an office lease. Numen is owned by a shareholder of APC.

During the three and six ended June 30, 2021 and 2020, APC paid approximately $0.4 million and $0.4 million, respectively, and $0.7 million and $0.7 million, respectively, to One MSO, Inc. (“One MSO”) for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 4).

The Company has agreements with Health Source MSO Inc., a California corporation (“HSMSO”), Aurion Corporation (“Aurion”), and AHMC Healthcare Inc. (“AHMC”) for services provided to the Company. One of the Company’s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company’s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
AHMC – Risk pool, capitation, claims payment	$	12,696	$	6,057	$	25,793	$	18,056
HSMSO – Management fees, net	(31)		(189)		(108)		(321)
Aurion – Management fees	(77)		(53)		(152)		(128)

Receipts, net	$	12,588	$	5,815	$	25,533	$	17,607

The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June 30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $14.2 million and $10.2 million, respectively, and $31.2 million and $21.0 million. $63.8 million and $45.3 million remained outstanding as of June 30, 2021 and December 31, 2020, respectively.

During the three and six months ended June 30, 2021 and 2020, NMM paid approximately $44,000 and $0, respectively, and $44,000 and $27,000, respectively, to an ApolloMed board member for consulting services.

In addition, affiliates wholly owned by the Company’s officers, including the Company’s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company’s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related-party transactions.

For equity method investments, loans receivable and line of credits from related parties, see Notes 4, 5, and 8, respectively.